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A nonmyeloablative chimeric mouse model accurately defines microglia and macrophage
contribution in glioma
Aims: Resident and peripherally derived glioma associ-
ated microglia/macrophages (GAMM) play a key role in
driving tumour progression, angiogenesis, invasion and
attenuating host immune responses. Differentiating
these cells’ origins is challenging and current preclini-
cal models such as irradiation-based adoptive transfer,
parabiosis and transgenic mice have limitations. We
aimed to develop a novel nonmyeloablative transplan-
tation (NMT) mouse model that permits high levels of
peripheral chimerism without blood-brain barrier (BBB)
damage or brain infiltration prior to tumour implanta-
tion. Methods: NMT dosing was determined in C57BL/
6J or Pep3/CD45.1 mice conditioned with concentra-
tions of busulfan ranging from 25 mg/kg to 125 mg/
kg. Donor haematopoietic cells labelled with eGFP or
CD45.2 were injected via tail vein. Donor chimerism
was measured in peripheral blood, bone marrow and
spleen using flow cytometry. BBB integrity was assessed
with anti-IgG and anti-fibrinogen antibodies. Immuno-
competent chimerised animals were orthotopically
implanted with murine glioma GL-261 cells. Central
and peripheral cell contributions were assessed using
immunohistochemistry and flow cytometry. GAMM
subpopulation analysis of peripheral cells was per-
formed using Ly6C/MHCII/MerTK/CD64. Results: NMT
achieves >80% haematopoietic chimerism by 12 weeks
without BBB damage and normal life span. Bone mar-
row derived cells (BMDC) and peripheral macrophages
accounted for approximately 45% of the GAMM popu-
lation in GL-261 implanted tumours. Existing markers
such as CD45 high/low proved inaccurate to determine
central and peripheral populations while Ly6C/MHCII/
MerTK/CD64 reliably differentiated GAMM subpopula-
tions in chimerised and unchimerised mice. Conclusion:
NMT is a powerful method for dissecting tumour micro-
glia and macrophage subpopulations and can guide
further investigation of BMDC subsets in glioma and
neuro-inflammatory diseases.
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Introduction
Glioblastoma is the most frequent primary brain
tumour in adults and one of the most aggressive types
of solid cancer. Patients with glioblastoma survive an
average of 6 months if left untreated and 12–
18 months when treated with maximal safe surgical
resection and postoperative radio-chemotherapy [1,2].
Despite intensive research, new treatment regimens
have neither led to substantial improvement of progres-
sion-free and overall survival, nor shown significant
reduction in disease and treatment-related morbidity
[3]. Reasons for slow progress towards improving out-
comes include intra- and intertumour heterogeneity,
the lack of adequate preclinical models and the role of
the tumour microenvironment in sustaining progres-
sion and treatment resistance [4–6].
The glioma microenvironment is complex and
heterogeneous [7]. It consists of extracellular matrix,
reactive astrocytes, glioma-associated microglia and
macrophages (GAMMs), endothelial cells, fibroblasts
and soluble factors. These cells contribute to tumour
progression but the complexity of their interactions
with neoplastic cells makes the modelling of the glioma
microenvironment challenging. GAMMs increase sub-
stantially with tumour grade, accounting for over 30%
of the lesion [5,8,9]. They promote progression by
favouring cell survival, proliferation, migration and
angiogenesis [10–14]. Gliomas were found to be signifi-
cantly smaller in animals with impaired or absent
microglia vs. those with normal microglia which fur-
ther supports the role of GAMMs in glioma progression
[15]. The composition of GAMMs is still a matter of
debate, with studies suggesting that bone marrow
derived cells (BMDC) account for the predominant pop-
ulation [16,17]. Investigating and targeting GAMMs
remains challenging. Activated microglia and BMDC
are morphologically indistinguishable and their pheno-
type as determined by lineage-specific antibodies shows
significant overlap.
In many studies, the distinction between microglia
and peripheral macrophages relied on CD45 [18,19]
however, such separation has recently been challenged
with evidence that microglia in gliomas can increase
CD45 expression [18–20]. Modelling GAMMs is also
beset by technical difficulties. Myeloablation obtained
by irradiating animals damages the blood brain barrier
(BBB) both directly, when the head is not shielded, and
indirectly by eliciting a potent systemic inflammatory
response [21]. BMDCs are mobilised in the circulation
by proinflammatory cytokines and can easily penetrate
the brain when the BBB is permeable [22]. Genetic
reporter models using flt3-GFP permit labelling and dis-
tinction of microglia vs. BMDC but not the manipula-
tion of the bone marrow (BM) compartment [23].
An accurate account of the contribution of microglia
and BMDC to GAMM populations would allow us to
gain a better understanding of their heterogeneity and
develop therapeutic strategies aimed at manipulating
microglia and the bone marrow derived compartment.
In order to investigate the complexity of GAMMs with-
out the damaging effects of irradiation, we developed a
nonmyeloablative model using a low-dose busulfan reg-
imen to achieve complete peripheral hematopoietic chi-
merism in the absence of BBB damage or central
chimerism. Busulfan is a DNA alkylating agent used in
clinical practice as a myeloablative conditioning agent
either alone or in combination with cyclophosphamide
prior to bone marrow transplantation (BMT) [24].
Peripheral chimerism in an immunocompetent animal
is followed by orthotopic implantation of the syngeneic
GL-261 glioma cell line to generate an aggressive
glioma that closely replicates human glioblastoma. This
preclinical model is the first that allows for a detailed
study of the extent and contribution of bone marrow
derived cells to glioma progression.
Methods
Lentiviral vector construction and production
Lentiviral vector (LV) plasmid containing the transgene
DsRed Express 2 (DSX2; Clontech Laboratories, Moun-
tain View, CA, USA) was constructed by replacing the
enhanced Green Fluorescent Protein (eGFP) gene cas-
sette in pHR.sin.SFFV.eGFP.att.wpre (gift from Dr Steve
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Howe; University College London) with the DSX2 gene
using Gateway technology (Life Technologies, Paisley,
UK) [25,26]. LVs were generated by transfection of
HEK 293T cells with pMD2G, pD8.91gag/pol32 and
pHRsin.SFFV. att.DSX2.wpre or pHRsin.SFFV.eGF-
P.att.wpre plasmids in a 2:1:1 ratio using polyethylen-
imine (PEI, Polysciences, Warrington, PA, USA).
Quantitative PCR was used to determine the number of
integrated LV genomes per cell and the infectious titre
was calculated as shown previously [27].
Glioma cell culture
GL-261 cells (National Cancer Institute, Frederick, MD,
USA) were cultured in RPMI-1640 (Sigma-Aldrich,
Dorset, UK), 10% Foetal Calf Serum (FCS) and L-Gluta-
mine (1 mM) without antibiotics. Labelled GL-261 lines
were generated via transduction with LV-SFFV-eGFP or
LV-SFFV-DSX2 [25]. Flow cytometric cell sorting to
remove nontransduced cells was done using BD FACS
Aria flow cytometer (BD Biosciences, Oxford, UK).
Animal maintenance
Experimental mice were housed in individually venti-
lated cages with a 12-h light/dark cycle with food and
water provided ad libitum in accordance with the Ani-
mal (Scientific Procedures) Act, 1986 (UK), under pro-
ject license number PPL40/3658 with ethics board
approval.
Bone marrow transplantation
8-10 week old female transplant recipients, C57BL/6J
CD45.2 (Harlan Laboratories, Bicester, UK) or PEP-3
CD45.1; (B6.SJL-PtprcaPepcb/BoyJ), received acidified
water (pH = 2.8) and irradiated diet the week prior to
transplant, in order to prevent gastrointestinal infection.
Conditioning consisted of 25 mg/kg/day of busulfan
(Busilvex, Pierre Fabre, Boulogne, France), with total
doses of 25 mg/kg, 50 mg/kg, 75 mg/kg or 125 mg/kg,
delivered via the intraperitoneal route. Whole bone mar-
row (2–3 9 107 cells in 200 ll Phosphate Buffered Sal-
ine (PBS)) was delivered via the tail vein, within 24 h of
receiving the final busulfan injection. Donor bone mar-
row was prepared from 8 to 10 week old female OK-
GFP mice (C57BL/6-Tg(CAG-EGFP)10sb/J (“OKABE”),
Jackson Laboratories, Bar Harbor, ME, USA) or C57BL/
6J, (CD45.2) mice as described previously [20]. Periph-
eral blood chimerism and cell population reconstitution
(anti-mouse CD45.2-PE, anti-mouse CD3-PE-Cy5, anti-
mouse CD19-APC-Cy7, anti-mouse CD11bPE-Cy7),
was determined using flow cytometry analysis of tail
vein bleeds taken at 4, 8 and 12 weeks post-transplant
(BD FACS Canto II flow cytometer, BD Bioscience,
Oxford, UK). The percentage eGFP was normalized to
the mean percentage eGFP detection in OK-GFP periph-
eral blood (70%) (Figure S1C). For whole brain flow
experiments, CD45.1 mice with >80% peripheral
CD45.2+/eGFP+ BM chimerism at 12 weeks were
intracranially implanted with GL-261 brain tumours
(n = 6) and compared to sham intracranial PBS injec-
tion (n = 5), or no injection (n = 2).
Stereotactic injection of glioma cells into intracranial
compartment
Chimeric mice (12 weeks post-transplant with 25 mg/
kg busulfan) were anaesthetized using isoflurane (Abbott
Laboratories, Maidenhead, UK). 5 9 104 GL-261 cells or
PBS (sham control) were injected into the striatum
2 mm lateral, and 3 mm deep to bregma [28] via single
burr hole using a Hamilton syringe (Hamilton, Reno,
NV, USA). Mice received standard postoperative care
and brains were harvested at 7, 14 and 17 days.
Sample processing
Mice were terminally anaesthetised and transcardially
perfused with Tyrode’s buffer to minimize confounding
peripheral blood artefacts. For histopathological and
immunohistochemical analysis, brains were fixed in 4%
paraformaldehyde (PFA)/PBS. Two tumour bearing
brains and two control brains were then processed to
paraffin embedding while the others were incubated in
30% sucrose/2 mM MgCl2/PBS for 24 h at 4°C and
stored at 80°C. Six coronal slices from the same areas
of bregma (0.98, 0.26, 0.46, 1.18, 1.94, and
2.62 mm; Figure S2) from each mouse. For whole
brain dissociation, specimens were placed in ice-cold PBS
without calcium or magnesium (Lonza, Slough, UK).
Tissue analysis and immunohistochemistry
One section from each frozen brain and one section from
FFPE brains were stained with haematoxylin-eosin. The
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level of brain engraftment, extent of GAMMs and
proliferation were determined on consecutive sections of
frozen and fixed brains using immunoperoxidase
immunohistochemistry with antibodies directed
against eGFP (Abcam, rabbit polyclonal, Cambridge,
UK; dilution 1:3000), Iba1 (Wako, polyclonal Osaka,
Japan; dilution 1:250), Ki67 (Abcam, rabbit poly-
clonal, Cambridge, UK; dilution 1:250) and Tmem119
(Abcam, Cambridge UK, rabbit polyclonal, dilution
1:50). Permeability of the BBB was tested using a
previously described protocol in stroke studies [29].
Biotinylated anti-mouse IgG (Vector Laboratories,
Peterborough, UK; Dilution 1 in 500) and anti-fibrino-
gen (Dako, Ely,Cambridgeshire UK, rabbit polyclonal,
dilution 1:50 000) antibodies were used. Briefly, after
washings in PBS, the sections were incubated with
biotinylated secondary antibodies followed by Avidin-
Biotin Complex (Vector Laboratories, Peterborough,
UK). The reactions were developed with the DAB-
peroxidase kit (Vector Laboratories, Peterborough,
UK), using identical developing times for all sections
[30]. Sections were then washed and rehydrated.
Nuclear counterstaining was performed with Mayer’s
haematoxylin. Slides were finally coverslipped in DPX
mounting medium (Leica, Milton Keynes, United Kingdom).
Triple immunofluorescence was performed on free
floating sections. They were stained using anti-mouse
eGFP, Iba1, CD11b (Abd Serotec, Oxford, UK; Dilution
1:250) antibodies with the appropriate fluorescent sec-
ondary antibodies [21] (1 lg/ml). Three sections were
used for staining and mounting: 1 at maximal tumour
dimension, and sections taken at 240 lm intervals
before and after the maximum dimension section. Slides
were scanned using the Pannoramic 250 Flash auto-
mated scanning microscope (3D Histech, Budapest,
Hungary) and viewed using Pannoramic viewer soft-
ware (3D Histech).
Image analysis
Quantification of donor cells in peritumoural, tumoural and
sham injected areas To demonstrate that eGFP+ (donor-
derived) cells were primarily located within the tumour
borders, eGFP+ cells were counted using FIJI [31] in
representative section for each condition. Five high
power fields were selected in the peritumoural area, the
intratumoural area and the ipsilateral parenchyma in a
sham injected animal. Automated counting was
performed using the analyse particles plugin
(Figure S6).
Quantification of immune cell subtypes in tumour bearing
brains Images (940 magnification) were captured in
Tagged Image file Format (TIFF) format and analysed
using Cellprofiler software [32]. The analysis pipeline
was configured to identify five categories of cells on
fluorescence imaging: (i) eGFP+ cells (peripheral cells),
(ii) Iba1+ cells (microglia/macrophages), (iii) co-
localizing Iba1+/eGFP+ cells (peripherally derived
macrophages), (iv) eGFP only cells = [eGFP+ cells] –
[Iba1+/eGFP+ cells] (peripherally derived non-GAMM
cells), (v) microglia = [Iba1+ cells] – [Iba1+/eGFP+ cells].
Quantification of donor cells in nontumour chimeras eGFP+
(donor-derived) and Iba1+/eGFP (microglial) cells
were counted using HistoQuant software (3D Histech)
in all six sections from each mouse. Automated
counting was optimised against a manual count of
three single sections, to avoid false positives and
negatives, until 95% accuracy was reached. Objects in
eGFP+ stained untransplanted wild type (WT) controls
(n = 8) were counted to obtain a mean background
value which was subtracted from the mean of the
transplanted groups. To assess proliferation, Ki67+ cells
were counted in six consecutive sections using
HistoQuant software, with staining around the choroid
plexus and on the very edge of the sections excluded,
and validated against manual counting as above. The
manual count showed an overestimation of Ki67+ cells
for each group, therefore a percentage overestimation
was determined and removed from the data generated
by the software.
Whole brain dissociation
Dissociation of cerebral hemisphere was adapted from
Robinson et al. with modifications [33]. Different con-
centrations of Percoll were prepared by mixing nine
parts Percoll (Sigma-Aldrich) with 1 part of 10X PBS
(Lonza, Slough, UK) to make an isotonic solution. 35%
and 70% Percoll were then constituted with standard
1X PBS.
Mice were perfused with cold PBS/5 mM EDTA
(Sigma-Aldrich). The brain was divided into tumour
and nontumour bearing hemispheres in a sterile Petri
dish and each digested with 1 mL Accutase (Merck
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Millipore, Darmstadt, Germany) for 30 min at 37°C.
Samples were mechanically dissociated through a
100 lm cell strainer (Corning, New York, NY, USA)
using syringe plungers. The cell strainer was washed
with 2% FCS/2 mM EDTA/PBS (FEP) until clean and
the sample centrifuged at 280G for 5 min at 4°C.
Supernatant was discarded and the cells purified from
myelin by resuspending the pellet in 35% Percoll and
underlaying with 70% Percoll. The homogenate was
centrifuged at 650G without brake for 10 min at room
temperature. The myelin layer at the surface was
removed and a thin milky layer of cells at the 35%/
70% interface was aspirated and resuspended with
5 ml of FEP. The cell suspension was centrifuged at
400G for 5 min at 4°C and the supernatant removed.
The cell pellet was then resuspended with 200 ll 2%
FCS/PBS for flow cytometry.
Cell preparation and analysis using flow cytometry
Cells were counted and aliquoted at a maximum density
of 1 9 106 cells per well in a 96-well plate (Corning,
New York, NY, USA). Cells were fixed with 1%
paraformaldehyde (PFA) at room temperature and a
Live/Dead Blue cell viability stain was performed (Life
Technologies, UK). Samples were then blocked with
45 ll of 5% mouse serum (Vector Laboratories, USA) 2%
FCS/PBS for 15 min and stained with a freshly made
master mix of antibodies in a volume of 25 ll/sample
(Table S1). After staining, cells were washed twice with
2% FCS/PBS and suspended in 200 ll 2% FCS/PBS prior
to analysing samples on flow cytometry (BD LSR For-
tessa; BD Biosciences, Oxford, UK). Compensation was
performed using UltraComp beads (eBiosciences, San
Diego, CA, USA), Amine Reactive beads for live/dead
staining (ThermoFisher Scientific, Waltham, MA, USA)
and OK-GFP peripheral blood for eGFP detection. Fluores-
cence minus one (FMO) controls were used instead of iso-
type controls to delineate gating margins and determine
true antibody staining. Blood and bone marrow samples
from each animal were also analysed to determine rela-
tive CD45.2 chimerism. FlowJo v10 10.0.8r1 was used
to analyses all samples (FlowJo LLC., Ashland, OR, USA).
Statistical analysis
Preliminary analysis Data transformation: Exclusion
criteria: Animals which did not display donor
chimerism (n = 1) were excluded from analysis,
animals with low levels of chimerism (<50%) were also
not used in subsequent experiments. Cell count data
from immunohistochemistry slides was converted into
percentages of total, however, differences between
groups was analysed using raw cell count data.
Primary analysis Assumption of normality was
checked using D’Agostino & Pearson omnibus
normality test and all cell count data sets passed. Data
were analysed using either Student’s t-test for
comparison between two groups or one-way ANOVA,
with Tukey’s post-hoc correction for multiple
comparisons. Time course groups were independent.
For flow cytometry data, results were reported as the
mean of the experiments per antibody panel. Statistical
significance was defined as an alpha of 0.05. Statistical
analysis was performed using the software package
Prism 6 (version 6.0 g; Graphpad Software, USA).
Results
Low-dose busulfan achieves high levels of peripheral
haematopoietic chimerism without perturbation of
the BBB
In order to determine if peripheral chimerism could be
achieved in the absence of either brain chimerism or
damage to the BBB, regimens of busulfan conditioning
at 25, 50, 75 or 125 mg/kg were given to syngeneic
sex-matched mice prior to transplant. Busulfan condi-
tioning was followed by tail vein injection of eGFP+
whole bone marrow cells (Figure 1A). The efficiency of
eGFP+ donor cell chimerism was assessed using flow
cytometry 12 weeks post-transplant. All busulfan-con-
ditioned recipients showed significant eGFP+ chimerism
in blood, spleen and bone marrow compared to non-
transplanted littermates (P < 0.001) (Figure 1B and
Figure S1A). Mice showed normal reconstitution of
CD11b+ monocytes, CD3+ T-cells and CD19+ B-cells
(Figure S1B). Over time, peripheral chimerism
increased from 4 to 12 weeks with 25 mg/kg busulfan
(Figure S1C) and normalized donor eGFP chimerism
averaged 70% at 12 weeks (Figure S1D).
Donor-derived brain engraftment was determined by
quantifying the number of eGFP+ cells (Figure S2) in
tissue sections. No difference in eGFP+ cell infiltration
was observed between mice receiving 25 mg/kg
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Figure 1. eGFP+ donor chimerism was achieved in the bone marrow but not in the brain of 25 mg/kg busulfan-conditioned transplant
recipients. (A) 2 9 107 eGFP+ bone marrow (BM) cells were delivered via the tail vein of C57BL/6J (WT) mice that received either 25, 50,
75 or 125 mg/kg busulfan. Untransplanted C57BL/6J and OK-GFP+ mice were included as controls (n = 8 mice/group). (B) Bone marrow
and brain chimerism, as well as blood-brain barrier (BBB) permeability by IgG staining, were determined 8 weeks post-transplant. No
changes in BBB permeability were observed. (C) Brain chimerism was established by counting eGFP+ cells from six coronal sections per
mouse using HistoQuant software (Bregma; 0.98, 0.26, 0.46, 1.18, 1.94 and 2.62 mm; 1 to 6; see Figure S2). Brain section 4 is
shown with the boxed area enlarged to highlight eGFP+ donor-derived cells. ***P < 0.001. Error bars represent the SEM. Bar = 25 lm.
© 2018 The Authors Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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busulfan and nontransplanted controls (Figure 1B, Fig-
ure S2). In contrast, a stepwise increase in eGFP+ cell
infiltration was seen from 50 mg/kg upwards, with
animals treated with 125 mg/kg dose having a 6-fold
increase over 75 mg/kg and a 45-fold increase com-
pared with the 25 mg/kg group (P < 0.001) (Fig-
ure S2B). A significantly larger brain area infiltrated by
eGFP+ cells was found in 125 mg/kg busulfan-condi-
tioned recipients compared with lower doses. No signifi-
cant differences were observed between the doses of 25
and 50 mg/kg.
The number of Iba1+ (resident and peripheral macro-
phages) and eGFP+ cells (donor macrophages) was
quantified using automated software on 6 coronal sec-
tions per animal to determine the percentage of donor
cells within the Iba1+ population (Figure S3).
In the 125 mg/kg group, 20% eGFP+ donor cells
were observed compared to 2% in both the 50 and
75 mg/kg group, and 0.7% in the 25 mg/kg group
(Figure 1B). In the group treated with 25 mg/kg, the
0.7% eGFP+ donor population was restricted to periph-
erally derived perivascular and choroid plexus macro-
phages and therefore did not represent true
engraftment. Animals treated with 25 mg/kg of busul-
fan showed only a few perivascular eGFP+ cells while
mice treated with 125 mg/kg busulfan showed wide-
spread and evenly distributed ramified eGFP+ cells (Fig-
ure 1C).
Ki67 staining was quantified to determine any effect
on proliferation of the conditioning regimen (Fig-
ure S3A). No microglial proliferation was observed with
any of the busulfan doses. Overall, we observed no
changes in Iba1+ cell numbers in the brain with
25 mg/kg busulfan by 8 weeks post-transplant. The
absence of perivascular deposits of IgG and fibrinogen
in the brains of mice receiving any dose of busulfan
conditioning and in controls at 8 weeks post-transplant
suggested the BBB was not affected (Figure 1B & Fig-
ure S4 & S5).
Bone marrow derived cells migrate to tumours in
nonmyeloablative transplant
Having established that nonmyeloablative transplant
does not perturb microglia, we used this model to dif-
ferentiate microglia from peripheral cell infiltration in a
syngeneic model of glioma. GL-261 mouse glioma cells
were orthotopically implanted into immunocompetent
animals and were sacrificed at the onset of neurological
deficits at approximately 17 days. A DSred expressing
GL-261 cell line demonstrated significant eGFP+ periph-
eral donor cell infiltration. Infiltrating cells were mainly
seen within the tumour bulk with some at the tumour/
brain interface (Figure 2A–F). Cells were quantified
using image analysis software (Figure S6).
Tumours generated by implanting GL-261 cells had
features resembling human glioblastoma. They were
composed of sheets of densely packed, severely atypical
cells with eosinophilic or fibrillary cytoplasm and irreg-
ular, hyperchromatic nucleus; several neoplastic multi-
nucleated cells were also present (Figure 3A,B); mitotic
activity was brisk (Figure 3C), endothelial and capillary
proliferation (Figure 3D) and microfoci of necrosis (Fig-
ure 3E). Lesions were focally infiltrative but never
showed extensive invasion of the hemisphere unilateral
and contralateral to the tumour site (Figure 3F).
Brain sections were divided into: (i) tumour, (ii)
tumour/brain interface and (iii) the rest of the brain
(Figure 2G). Considerable infiltration by peripheral
Iba1+/eGFP+ macrophages, with many resident Iba1+/
eGFP microglia were present within the tumour (Fig-
ure 2G right upper quadrant). In contrast, the donor
macrophages were mainly confined to the tumour/
brain interface. PBS injected controls did not exhibit
any eGFP+ cell infiltration (data not shown). Iba1+/
eGFP microglia had a ramified morphology in the
contralateral nontumour bearing hemisphere (Fig-
ure 2G left lower quadrant) while features changed to
amoeboid in the proximity to the tumour margins (Fig-
ure 2G right lower quadrant). There was no difference
in the morphology of peripherally derived eGFP+ and
centrally derived eGFP cells. Tmem119-positive micro-
glia was seen both within the tumour and at the
tumour/brain interface (data not shown).
Peripheral macrophages form up to 50% of the Iba1
positive tumour GAMM population and their
proportion does not change significantly over time
We wanted to determine the timing of BMDC migra-
tion. Time course experiments at 7, 14 and 17 days
showed overall peripheral infiltration of 10–15% of
Iba1/eGFP+ BMDCs with 36–41% Iba1+/eGFP+
peripheral macrophages and 42–52% Iba1+/eGFP
microglia. The peripheral Iba1 cells represent other
leucocyte populations (T-cells and granulocytes, data
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not shown). A significantly higher microglial density
than peripheral derived macrophages was seen in the
brain on day 7 (322.4 vs. 215.4, P < 0.0001) (59%
vs. 41%) and day 17 (271.1 vs. 181.2, P = 0.0029)
(56% vs. 44%), but not on day 14 (221.5 vs. 215.8,
P = 0.9034) (50% vs. 50%) suggesting that peripheral
(A) (B)
(C) (D)
(E) (F)
Figure 3. Histopathological features of GL-261 tumours. The tumour is composed of densely packed, severely atypical cells with
scanty or fibrillary cytoplasm; a few gemistocytes are seen (A - Haematoxylin-Eosin, X10); severely atypical cells with eosinophilic
cytoplasm and one or multiple irregular, hyperchromatic nuclei are hallmark of this tumour (B – Haematoxylin-Eosin, X40); the lesion
shows brisk mitotic activity (C – Haematoxylin-Eosin, X40) endothelial and capillary proliferation (D - Haematoxylin-Eosin, X40) and
microfoci of necrosis (E – Haematoxylin-Eosin, X40 - arrow); the tumour/brain interface shows focal infiltration of the adjacent brain
(F - Haematoxylin-Eosin, X40).
Figure 2. Immunofluorescent staining of syngeneic GL-261 tumours in nonmyeloablative transplant mice. (A) Schematic diagram
showing the experimental design using Nonmyeloablative transplantation with Busulfan at 25 mg/kg followed by implantation of GL-
261 tumour 12 weeks later, and brain harvest 17 days post implantation. (B) Anti-DsRed staining in a chimerised animal implanted
with GL-261_DSX2 tumours. White dotted line delineates tumour border (scale bar = 1000 lm). (C) Anti-eGFP staining to demonstrate
BMDC within the brain of a chimerised animal; peripheral eGFP+ cells are mainly confined to within the tumour mass. (D) 30 lm
thickness coronal section of tumour bearing brain. Combined merged image of anti-DsRed (tumour), anti-eGFP (BMDC) and DAPI
(nuclei). (E) X40 high powered field of intratumoural region demonstrating infiltrating eGFP+ BMDC (scale bar = 100lm). (F)
Intraparenchymal, peritumoural region showing lesser degree of eGFP+ BMDC infiltration. (G) Merged picture of anti-eGFP staining
(Green - BMDC), anti-Iba1 staining (Red - microglia/macrophage) and anti-CD11b (Cyan - myeloid cells) staining. Four quadrant high
powered fields (X40) demonstrating staining pattern for each region of interest (white boxes). Upper Right Panel: Intratumoural region of
interest. Bottom Right Panel - Peritumoural region of interest. Bottom Left Panel – Nontumour brain parenchyma in contralateral
hemisphere. Inset within each panel shows representative cell morphology.
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infiltration occurs early in tumour progression and is
established by day 7. Microglia were the primary con-
tributors to GAMMs although peripheral macrophages
were in nearly equal numbers (Figure 4A–E).
CD45.1/CD45.2 distinguishes peripheral
macrophages from microglia in the brain more
effectively than eGFP on flow cytometry
To further confirm the results obtained with eGFP, we
used the pan-leucocyte congenic CD45.1 model (PEP-
3). CD45.1 can be distinguished from the CD45.2
(C57BL/6J) epitope with accuracy close to 100% by
flow cytometry. In contrast with eGFP, however, these
markers are more difficult to detect using immuno-
chemistry. We transplanted CD45.2+/eGFP+ whole
donor bone marrow into a CD45.1+ host and compared
the percentage of eGFP chimerism with the percentage
of CD45.2 chimerism post nonmyeloablative transplant.
Samples were gated (Figure S7A) to select for live sin-
glet CD45+ cells. eGFP+ expression was only detectable
in 43% of CD45.2 donor cells in BM or 55% in the
brain (Figure S7B) as expected, whilst eGFP+ cells were
>99% CD45.2+. eGFP expression was higher in blood
at approximately 70–75% of donor cells. CD45.2/
CD45.1 therefore distinguished much more accurately
between donor and recipient within the brain with lit-
tle or no double staining overlap (Figure 5A–D). Fur-
thermore, we achieved an average of 88.4% donor
peripheral blood chimerism and 92.4% BM donor chi-
merism (Figure 5E).
Using CD45.1 recipients with >80% peripheral
CD45.2+/eGFP+ blood chimerism, we intracranially
implanted GL-261 cells and compared the resulting
glioma to sham intracranial PBS injection or noninjec-
tion controls (Figure 5A–D). The tumour bearing brain
hemisphere contained on average 67% peripheral
CD45+ cells while on average 4.7% peripheral cells
were detected in the brain of the sham injected control
group (Figure 5E). The nontumour bearing hemisphere
also showed average 20% infiltration (Figure 5E),
whilst un-injected mice had 2.5% peripheral infiltration
(Figure 5D).
A four-marker panel of Ly6C/MHCII/MerTK/CD64
allows accurate distinction between GAMM
populations in chimerised and unchimerised mice
A four-marker panel of Ly6C/MHCII/MerTK/CD64 was
applied to determine the individual subpopulations of
immune cells present in the tumour microenvironment
by combining the lineage tracing ability of NMT and
marker sets previously used to distinguish monocyte
and macrophage populations within the gut and tissue
macrophages (Figure 5F) [34,35].
Within the tumour bearing hemisphere, granulocytes
(SSChi/MHCII) accounted for 40.2% of all CD45+ cells;
T and B cells (CD11b/CD3+/CD19+) 16.7%, and the
GAMM population made up 29.9% of total CD45+ cells
(Figure 5G). The CD45+ population could be subdivided
into peripheral/donor (CD45.2+) and central/host
(CD45.1+) (Figure 5G). Peripheral donor inflammatory
monocytes (MHCII/Ly6C+) accounted for 1.7% of
CD45+ cells, peripheral undifferentiated macrophages
(MHCII+/Ly6C+) 4.9% and peripheral differentiated
macrophages (MHCII+/Ly6C) 0.9%; CD45.1+ host
microglia accounted for 22.4% and were identified as
Ly6Clow/, using the MHCII/Ly6C waterfall gate previ-
ously described in addition to MerTK/CD64 (Figure 5G)
[35].
As a proportion of GAMMs, defined as CD11b+CD45+
cells minus granulocytes, T cells and B-cells;
Figure 4. Time course experiment quantifying the number of eGFP+ and Iba1+ cells present within the tumour mass over time. (A–C)
Vertical panels represent cells at the tumour margin (dashed white line) on Day 7, 14 and 17, respectively. From top to bottom: First
row = 30 lm thickness coronal section of tumour bearing brain (scale bar = 1000 lm). Second row = Iba1 staining with highlighted
cell (inset) to demonstrate morphology (scale bar = 100 lm). Third row = eGFP staining demonstrating eGFP+ BMDC located within the
tumour margin. Fourth row = merged image of Iba1 and eGFP staining. A significant number of Iba1+/eGFP(yellow) microglial cells
within the tumour, Iba1+/eGFP+ double positive (green) cells represent peripheral macrophages are almost found exclusively within
tumour, and Iba1/eGFP+ (blue) cells represent non-macrophage BMDC within the tumour. (D) Total cell counts: The majority of
infiltrating cells are Iba1+/eGFP (microglia). The next most frequently seen population are Iba1+/eGFP+ (peripheral macrophage),
followed by Iba1/eGFP+ (nonmacrophage BMDC) which is present at all time points, suggesting the presence of nonmacrophage derived
haematopoietic cells within the tumour. BMDC infiltration (eGFP+) occurs early in disease and the overall proportions do not significantly
vary over the time course. (E) Analysis of microglia vs. peripheral macrophage cell counts demonstrates a consistently higher microglial
population, which is significantly greater than the peripheral macrophage population at Day 7 (*** = P < 0.0001) and at Day 17 (* =
P < 0.05). There is no significant difference between microglial and peripheral macrophage cell counts at day 14.
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inflammatory monocytes accounted for 6.1%, undiffer-
entiated macrophages 17.0%, differentiated macro-
phages 3.6% and microglia 73.2%, making the total
peripheral contribution in the tumour bearing hemi-
sphere 26.7% (Figure 5H).
Sham injections led to 4.7% infiltration of donor
CD45.2+ cells into the brain, but they were predomi-
nantly T and B cells (86.3%) with the remaining por-
tion consisting of granulocytes. Any peripheral
infiltration seen were almost exclusively monocytes
(0.03%) (Figure S7C).
In tumour bearing animals, we also investigated the
immune cell fractions in the contralateral nontumour
bearing hemisphere. As a proportion of CD45+ cells
granulocytes accounted for 13.3%, T and B cells 17.9%
and undifferentiated macrophages 1.4% (Figure S7D).
As a proportion of GAMMs, cells were almost exclu-
sively microglia (96.7%). Results of previous experi-
ments are represented in Figures 5H.
The waterfall gating of MHCII/Ly6C separated
peripheral monocytes (MHCII/Ly6Chi) and peripheral
undifferentiated macrophages (MHCII+/Ly6Chi), how-
ever differentiated macrophages and microglia
(Ly6Clow/) required further separation. By using the
macrophage marker CD64 these two populations were
well separated with differentiated macrophages express-
ing CD64hi and microglia expressing CD64low. Further
confirmation of macrophage and tissue macrophage
status within GAMMs was done using MerTK, which
showed that all macrophages and microglia expressed
the tyrosine kinase MerTK, whereas monocytes did not
(Figure 5F). The peripheral/central origin of each sub-
population identified using this gating strategy was
checked by back-gating onto CD45.1/CD45.2 which
demonstrated >91% purity for each population (Fig-
ure 6A).
Siglec-H and CX3CR1 have both been purported to be
microglia-specific markers [36,37]. In a separate marker
panel, we also found that MerTK+/CD64+/Siglec-H+/
CX3CR1 consistently resulted in pure macrophage pop-
ulations with approximately 5% microglial contamina-
tion, but the (MerTK+/CD64+/Siglec-H+/CX3CR1+)
microglial population was 10–20% cross-contaminated
with monocytes and macrophages (Figure 6B) suggest-
ing a lack of specificity of both Siglec-H and CX3CR1 for
microglia in an inflammatory environment.
Concerns have also been raised regarding the validity
of CD45 in differentiating microglia from macrophages
in glioma [5,7,16,17]. To address this, we compared
CD11b/CD45 expression against our four-marker set
(Figure 7A). Selection of CD11b+/CD45+ cells effec-
tively removed T and B cell populations but resulted in
overlapping populations of SSChi/MHCII granulocytes
and all four GAMM subpopulations (Figure 7B).
Although CD11b/CD45 appears to separate differenti-
ated macrophages from microglia; monocytes and
undifferentiated macrophages overlay both peripheral
and central CD11b/CD45 populations, making the
CD11b/CD45 marker set limited in glioma (Figure 7B).
Finally, we validated the panel of Ly6C/MHCII/
MerTK/CD64 to differentiate GAMMs in unchimerised
mice. In the tumour bearing hemisphere, granulocytes
accounted for 15.1%, T-cell and B-cells 7.9%, and
GAMMs 60.8%. Relative peripheral GAMM contribu-
tion was 45.7% while central GAMM was 61% (Fig-
ure 7C). Marrow-derived GAMMs consisted of
monocytes 16.2%, undifferentiated macrophages 26.4%
and differentiated macrophages 3% (Figure 7D).
Figure 5. Characterising immune cell populations by flow cytometry in GL-261-implanted CD45.1/eGFP-CD45.2 nonmyeloablative
transplant mice. All flow plots used the initial gating strategy outlined in Figure S7A to show live singlet CD45+ cells. (A–D) Chimerism
comparison in blood, bone marrow and brain of tumour bearing hemisphere, sham-PBS injected hemisphere, contralateral nontumour
bearing hemisphere of mice implanted with GL-261 cells and uninjected brain of chimeric mouse. Quadrant plots were used to show the
relative proportion/chimerism of CD45.2 (donor) vs. CD45.1 (host) cells. (E) Relative CD45.2 donor chimerism of blood, bone marrow
and brain in a tumour bearing hemisphere (black), the contralateral nontumour bearing hemisphere in the same animal (beige) and
sham-injected hemisphere of a different animal (blue). (F) Gating strategy used to identify multiple tumour-tropic immune cells within the
tumour bearing hemisphere of a mouse. Host cells were distinguished from peripheral donor cells using CD45.1 and CD45.2 marker
expression, respectively. Sequential gating strategies using SSC/MHCII and CD11b/lineage depletion was used to remove granulocytes, T-
cell and B-cells to obtain a GAMM population. Downstream gating with Ly6C/MHCII/MerTK/CD64 was then used to characterise GAMM.
(G) Relative proportions of each immune cell type. Immune cell types identified included: granulocytes, lymphocytes (T and B-cells) and
GAMMs. GAMMs were further subdivided into inflammatory monocytes, undifferentiated macrophages, differentiated macrophages and
microglia. (H) Proportion of subpopulations found within GAMMs in tumour (black) and nontumour bearing (brown) hemispheres.
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Discussion
We used a nonmyeloablative transplant (NMT) in mice
with low-dose busulfan to develop a novel brain
tumour chimeric model and investigate the contribu-
tions of BMDCs to the glioma microenvironment. We
obtained high levels of chimerism without damaging
the BBB or impacting on animal health and life-expec-
tancy. We also demonstrated that recruitment occurs
early in the disease and that the overall proportion of
central vs. peripherally derived cells remains stable over
time.
Haematopoietic stem cells are highly sensitive to
busulfan [38,39]. Treatment with this drug at low
doses induces cellular senescence and replacement
with donor bone marrow without affecting the integ-
rity of the BBB [38,40–42]. Low-dose busulfan as a
nonmyeloablative model has not been previously
applied to the study of Central Nervous System (CNS)
tumours and was critical to our model [43]. This tech-
nique resulted in >80% peripheral chimerism by
12 weeks without accompanying brain engraftment.
Higher doses cause damage to resident immune cells
[38,44,45] and are known to mediate peripheral
immune cell migration into the CNS resulting in long-
term promigratory signals in the brain [21]. The
absence of noticeable morphological changes in micro-
glia or increase in their number compared to controls
suggested the dose of 25 mg/kg did not affect brain
resident inflammatory cells. In addition, NMT pre-
serves the BBB as proven by the lack of IgG and fib-
rinogen perivascular deposits in treated animals, prior
to the implantation of GL-261. Our model requires a
single intraperitoneal injection prior to donor BMT
and the procedure is well tolerated by recipient ani-
mals. Over 8–12 weeks, engrafted donor BM cells
became the dominant population. Such long lead
times represents a limitation of our model, but it also
gives the advantage of allowing post-transplant
inflammatory responses to resolve [21,44]. In addition
to achieving high levels of peripheral haematopoietic
chimerism, our myeloablative model showed low
toxicity and allowed for the preservation of BM home-
ostasis. Animals have normal life expectancy and are
not immunocompromised.
Our NMT model has several advantages over other
models. CD45.1 and CD45.2 are both pan-leucocyte
antigens commonly used in the context of adoptive
transfer experiments [46]. This approach has the
advantage of permitting a more efficient identification
of donor vs. host populations in flow cytometry com-
pared to eGFP. Adoptive transfer using whole body
irradiation with or without head shielding followed by
BMT is a cornerstone technique for the study of blood-
borne macrophages vs. microglia [47–52]. Nevertheless
this technique has significant drawbacks such as
decreased chimerism when the head is shielded and the
use of lethal doses of irradiation, which provokes a
long-term, radiation-induced systemic increase in
proinflammatory cytokines such as Tumour Necrosis
Factor-a, Platelet Derived Growth Factor, chemokines
CCL2 and CCR8 [21], and Interleukin-1 [53]. Parabio-
sis proposed by Ajami et al. attempted to overcome
these limitations by surgically anastomosing circula-
tions of donor and recipient animals [54]. However,
chimerism with this technique can be as low as 50%
leading to underestimation of BMDCs. Knock-in, lineage
tracing models exploiting microglial expression of the
fractalkine receptor CX3CR1-GFP and CX3CR1-CreERT
have increased the accuracy in distinguishing microglia
from peripherally derived cells but overlap still exists
due to CX3CR1 cross-expression in circulating mono-
cytes and peripheral and tissue macrophages [22].
Recently, Bowman et al. used a genetically engineered
mouse with Flt3:Cre;Rosa26:mTmG crossed with a Nes-
tin TVA glioma to interrogate the transcriptional profile
of microglia vs. BMDC [23]. Similar to other transgenic
animals, the technique allowed for efficient labelling of
microglia and BMDCs from the earliest stages of differ-
entiation but unlike NMT the technique does not per-
mit one to ‘swap out’ bone marrow compartments in
mature animals without cross-breeding (Table 1).
Figure 6. GAMM subpopulation analysis in GL-261 implanted nonmyeloablative conditioned mice. (A) Subpopulation purity analysis
using Ly6C/MHCII/MerTK/CD64 gating strategy; isolated cells were first separated using Ly6C/MHCII/MerTK/CD64 into 4 GAMM
subpopulations and the donor/host purity of each subpopulation was determined using CD45.2 (donor)/CD45.1 (host) expression level.
(B) A similar analysis was performed using microglia surface markers Siglec-H and CX3CR1. CD45+ cells were separated using MerTK/
CD64/Siglec-H/CX3CR1. Donor/host purity was then determined using CD45.2 (donor)/CD45.1 (host) expression. This gating strategy
showed that only 76.7% of cells in the microglial population were confirmed CD45.1+ host cells.
© 2018 The Authors Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
Nonmyeloablative chimeric mouse model of glioma 15
Our model was developed using the mouse glioma
cell line GL-261. This 3-methylcholantrene-induced cell
line is widely used as preclinical model of GBM as it is
highly reproducible and it closely replicates the human
counterpart. Lenting et al., suggest orthotopic implanta-
tion in syngeneic, immunocompetent animals can also
be regarded as an advantage to investigate glioma
microenvironment and its complex tumour–stromal
interactions [43,55–57]. The GL-261 model has recog-
nized limitations, which include focal infiltration of the
surrounding brain and high expression of MHCI, unlike
human GBM. Finally, similar to all models that require
cell implantation it has the limitation of orthotopic sur-
gery [56,57]. Previous studies with GL-261-derived
glioma demonstrated heterogeneous composition of
GAMMs using live-two photon imaging and FACS
Figure 7. Unchimerised mice implanted with GL-261. (A) CD11b+/CD45+ cells were selected and gated against cell surface markers
ordinarily used to characterise different immune populations: granulocytes, T and B-cells and GAMM. An overlay of all four immune
populations using CD11b/CD45 expression is shown (left overlay box). GAMM population was then selected (pink box) and each GAMM
subpopulation back-gated using CD11b/CD45. A second overlay demonstrates overlap of inflammatory monocytes, undifferentiated
macrophages, differentiated macrophages and microglia, thereby showing that CD45 expression does not adequately separate microglia
from other GAMM populations. (B) Relative proportions of each immune cell type. GAMM is the sum of inflammatory monocytes,
undifferentiated macrophages, differentiated macrophages and microglia. (C) Relative proportions of each GAMM subpopulation.
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analysis [58–60]. Pathological examination of the
implanted tumours in our experiments revealed fea-
tures similar to human GBM. Unlike other studies
[56,57], we only observed limited infiltration into the
surrounding brain, however, it is worth noting that
nontumour bearing hemispheres were significantly
inflamed and myeloid migration in this hemisphere was
influenced by the tumour. As such, contralateral hemi-
spheres should not be used as controls and instead
sham injected mice are more appropriate.
We confirmed that the CD11b+/CD45 low/high
approach showed considerable overlap between micro-
glia and blood-borne macrophages. Badie and Schart-
ner were the first to use flow cytometry to analyse
central vs. peripheral contributions to GAMMs in a rat
glioma model based on CD11b+/CD45low and CD11b+/
CD45high expression and found that microglia
accounted for 13-34% of the immune infiltrate, and
peripheral macrophages 4.6–12% [61]. However, the
reliability of CD45 has been questioned as its expres-
sion may change under environmental influence, par-
ticularly neuroinflammation [5,7,62]. Moreover,
stratification by CD45 expression alone potentially
masks myeloid subpopulations within the tumour. To
distinguish between resident and peripherally derived
GAMMs we therefore applied a four-marker gating
strategy for flow cytometry based on previous studies
[34,36]. We observed microglia to be the predominant
population within GAMMs with a contribution of
peripheral cells of approximately 45%. MerTK/CD64 is
a transcriptionally derived marker set used to define
macrophages in the peritoneum, spleen, lung and
brain [36], whereas Ly6C/MHCII is a commonly used
marker set to delineate monocytes [35]. Our, Ly6C/
MHCII/MerTK/CD64 gating strategy was chosen to
consolidate these two-marker approaches into one set
of markers. In inflammatory conditions, blood mono-
cytes (Ly6C+/MHCII) upregulate MHCII but retain
monocytic features to resemble undifferentiated
macrophages [63]. In contrast, Ly6C is downregulated
upon monocyte maturation to a macrophage [63]. By
overlaying the highly expressed macrophage markers
MerTK/CD64 macrophages were identified and further
subcategorized into resident and peripheral based on
the CD64 expression [36,64]. The recent discovery of
Tmem119 as a specific marker of microglia has simpli-
fied their separation in both human and mouse brains
using immunohistochemistry, flow cytometry and cell
sorting. Tmem119 is a transmembrane cell-surface
developmentally regulated protein of unknown func-
tion that is highly expressed on microglial cells but
not by macrophages or other immune cells [65]. Our
Table 1. Summary of different techniques used to distinguish microglia from BMDC in the CNS
Method Description Advantages Disadvantages
IR bone marrow
transplantation
[44,48]
Whole body irradiation followed by
labelled bone marrow rescue
High levels of chimerism, rapid
chimerism
Lethal dose radiation. Fulminant
systemic inflammatory response, BBB
damage
Head-shielded
bone marrow
transplantation
[16,17,47]
As above with lead shielding of
cranium.
Similar to above with protection
from BBB damage
Higher doses of irradiation required.
Significant systemic inflammatory
response
Parabiosis [54] Surgical anastomosis of labelled donor
and recipient blood circulations
Minimal systemic inflammatory
response. No perturbation of
BBB
Lower levels of chimerism (~50%).
Technically challenging
NMT Single injection of busulfan followed by
bone marrow transplantation
Technically simple. High levels
of chimerism, minimal
systemic inflammatory
response and perturbation of
BBB
Longer time to chimerism (12 weeks)
Genetic lineage
tracing studies
[23,59]
Transgenic mice expressing labelled cell
populations or genetically engineered
conditional labelling of specific myeloid
lineages
Highly accurate lineage
dependent labelling of different
cell types and myeloid
subpopulations
Costly and technically challenging.
Nonconditionally labelled single gene
marker systems (e.g. CX3CR1 labelled
transgenic mice) are less reliable at
distinguishing microglia from
macrophages in inflammatory
environments
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preliminary results on eGFP/Iba1 tissue sections are in
keeping with these findings and appear to confirm the
reliability of Tmem119 in differentiating microglia
from BMDC.
Recent years have witnessed a shift in focus in
glioma research from investigating the genetic and
molecular makeup of tumour cells to unravelling the
complexity of glioma microenvironment and its contri-
bution to progression and resistance to treatment
[7,66]. Interactions between resident and peripherally
derived inflammatory cells, the contribution of resident
cells and BMDCs in each tumour, the phenotype and
functions they acquire and their interplay with tumour
cells and glioma stem cells remain to be fully investi-
gated. Several lines of evidence support the relevance of
studying the glioma microenvironment. For instance,
selective ablation of CD11b+ myeloid cells using a con-
ditional ganciclovir activated CD11b-Herpes Simplex
Virus-Thymidine Kinase transgenic model in GL261
tumour bearing animals showed a survival benefit [15]
and a recent study by Sorensen and colleagues [67]
demonstrated a survival disadvantage in human
glioblastomas expressing high levels of the M2 pheno-
type maker CD163, CD204 and CD206. Gabrusiewicz
and colleagues [20] have shown an increase in circu-
lating BMDCs compared to healthy subjects which has
further fuelled interest in the contribution of these cells
to glioma progression and reinforced the concept that
mobilization and recruitment of BMDCs is a key event
in patients with glioblastoma.
In conclusion, we propose a novel model to investigate
the glioma microenvironment and the contribution of
resident and BMDCs. Although we share the concern
that data from murine models should be interpreted with
caution when applied to human glioblastoma
[20,43,60], the development of new models in healthy,
immunocompetent animals with preserved BBB, normal
brain environment, with the absence of systemic inflam-
mation nonetheless represent a powerful tool in further-
ing our understanding of tumour-host interactions.
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Supporting information
Additional supporting information may be found online
in the Supporting Information section at the end of the
article:
Figure S1. Donor chimerism was achieved in the blood
and spleen of busulfan-conditioned transplant recipi-
ents.
Figure S2. No significant levels of eGFP+ donor-derived
microglia were detected in the brains of 25mg/kg
busulfan-conditioned transplant recipients.
Figure S3. Quantification of total Iba-1+ microglia
demonstrated that busulfan did not induce a significant
proliferative response.
Figure S4. No significant changes in brain integrity
were observed in busulfanconditioned mouse brains.
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Figure S5. Tumour shows extravascular fibrin deposits
and some uptake in tumour cells
Figure S6. The graph represents the density of eGFP+
cells in the brain away from the tumour, within the
tumour mass and in sham controls
Figure S7. Flow cytometry gating analysis used to
determine live CD45+ cells, chimerism and immune cell
populations.
Table S1. Flow cytometry antibody panel and native
eGFP antigen used to characterise monocytes, periph-
eral bone-marrow derived macrophages and microglia
in brain, blood and bone marrow.
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